CDK18

Across TCGA pan-cancer cohorts, CDK18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDK18 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDK18 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDK18 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CDK18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.619	0.890	.024	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
CCRCC	DFS	Median	All	0.912	0.577	.012	2	view →
LSCC	DFS	Median	II,III,IV	0.964	0.878	.043	2	view →
HNSC	DFS	Median	II,III,IV	0.567	0.742	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDK18–PDAC (OS)

Open the PDAC breakdown →